Liver Fibrosis Resolution: From Molecular Mechanisms to Therapeutic Opportunities
Open accessThe DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Abstract
The liver is a critical system for metabolism in human beings, which plays an essential role in an abundance of physiological processes and is vulnerable to endogenous or exogenous injuries. After the damage to the liver, a type of aberrant wound healing response known as liver fibrosis may happen, which can result in an excessive accumulation of extracellular matrix (ECM) and then cause cirrhosis or hepatocellular carcinoma (HCC), seriously endangering human health and causing a great economic burden. However, few effective anti-fibrotic medications are clinically available to treat liver fibrosis. The most efficient approach to liver fibrosis prevention and treatment currently is to eliminate its causes, but this approach’s efficiency is too slow, or some causes cannot be fully eliminated, which causes liver fibrosis to worsen. In cases of advanced fibrosis, the only available treatment is liver transplantation. Therefore, new treatments or therapeutic agents need to be explored to stop the further development of early liver fibrosis or to reverse the fibrosis process to achieve liver fibrosis resolution. Understanding the mechanisms that lead to the development of liver fibrosis is necessary to find new therapeutic targets and drugs. The complex process of liver fibrosis is regulated by a variety of cells and cytokines, among which hepatic stellate cells (HSCs) are the essential cells, and their continued activation will lead to further progression of liver fibrosis. It has been found that inhibiting HSC activation, or inducing apoptosis, and inactivating activated hepatic stellate cells (aHSCs) can reverse fibrosis and thus achieve liver fibrosis regression. Hence, this review will concentrate on how HSCs become activated during liver fibrosis, including intercellular interactions and related signaling pathways, as well as targeting HSCs or liver fibrosis signaling pathways to achieve the resolution of liver fibrosis. Finally, new therapeutic compounds targeting liver fibrosis are summarized to provide more options for the therapy of liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, liver fibrosis is now recognized as a potentially reversible process, with resolution being closely linked to the reprogramming of macrophages towards restorative phenotypes characterized by enhanced efferocytosis, reduced pro-inflammatory signaling, and increased matrix degradation capacity.”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Resolution of fibrosis involves not only the degradation of ECM but also reprogramming of the immune microenvironment (87, 88).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909 · cited 1×
“HSC activation can be regulated by the Hippo pathway [65].”
BackgroundMechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
Heldin, C.-H., & Westermark, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1283 · Cited by 2,496 · cited 1×
“PDGF belongs to a group of growth factors whose physiological functions include controlling cell proliferation and migration and promoting the synthesis of vital components of the connective tissue matrix [23,61].”
BackgroundHepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485 · cited 1×
“Consequently, reducing the number of aHSCs, including inhibiting their proliferation or activation [7,24], promoting HSC apoptosis or autophagy [11,68,80], and deactivating the activated HSCs [76,77] to reverse liver fibrosis, may be an anti-fibrosis strategy [81].”
BackgroundMacrophages: master regulators of inflammation and fibrosis
Wynn, T., & Barron, L. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255354 · Cited by 1,392 · cited 1×
“Among them, hepatic macrophages (KCs), which are located within the lumen of the liver sinusoids [17], play crucial roles in liver fibrosis development [47].”
BackgroundLiver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061 · cited 1×
“The predominant macrophage populations in the initial stages of the damage are pro-inflammatory [46].”
BackgroundLiver sinusoidal endothelial cells: Physiology and role in liver diseases
Poisson, J., Lemoinne, S., Boulanger, C., Durand, F., Moreau, R., Valla, D., & Rautou, P.-E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.009 · Cited by 1,047 · cited 1×
“Although changing the phenotype of LSECs, this imbalance also helps to activate HSCs, which in turn encourages inflammation and liver fibrosis [43,44].”
BackgroundPathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894 · cited 1×
“Eliminating the chronic liver injury causes liver fibrosis to regress along with a decrease or disappearance of aHSCs [74].”
BackgroundTGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
Dewidar, B., Meyer, C., Dooley, S., & Meindl-Beinker, A. N. (2019) · Cells · doi:10.3390/cells8111419 · Cited by 837
Cited by
Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy
Seyhan, D., Allaire, M., Fu, Y., Conti, F., Wang, X. W., Gao, B., & Lafdil, F. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01308-4 · Cited by 164
“In contrast to its advanced cirrhotic state, liver fi brosis is reversible [28, 29].”
Yin, Y., Feng, W., Chen, J., Chen, X., Wang, G., Wang, S., Xu, X., Nie, Y., Fan, D., Wu, K., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00539-x · Cited by 137
“Chronic inflammation due to persistent liver damage can induce fibrosis by disrupting the normal healing response [18].”
BackgroundLiver Fibrosis Leading to Cirrhosis: Basic Mechanisms and Clinical Perspectives
Somnay, K., Wadgaonkar, P., Sridhar, N., Roshni, P., Rao, N., & Wadgaonkar, R. (2024) · Biomedicines · doi:10.3390/biomedicines12102229 · Cited by 70
Kidney Fibrosis: Fundamental Questions, Challenges, and Perspectives
Liu, Y. (2024) · Integrative Medicine in Nephrology and Andrology · doi:10.1097/imna-d-24-00027 · Cited by 74
Liu, W., Zhang, L., Wei, X., Xu, Y., Fang, Q., Qi, S., Chen, J., Wang, C., Wang, S., Qin, L., et al. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.121659 · Cited by 52
Jee, Y.-M., Lee, J., & Ryu, T. (2025) · Biomedicines · doi:10.3390/biomedicines13051260 · Cited by 70
“Liver fibrogenesis is induced by the activation of HSCs and the deposition of extra-cellular matrix proteins, including type I and III collagens [62].”
Lin, L., Li, X., Li, Y., Lang, Z., Li, Y., & Zheng, J. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.11.009 · Cited by 52
The Complex Interplay of TGF-β and Notch Signaling in the Pathogenesis of Fibrosis
Бакаленко, Н. И., Kuznetsova, E., & Malashicheva, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910803 · Cited by 48
“Fibrosis can occur in nearly any organ including the liver, kidney, lung, heart, and skin [3–7].”
BackgroundThe evidence-based multifaceted roles of hepatic stellate cells in liver diseases: A concise review
Kim, J., & Kim, Y. J. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122547 · Cited by 43
Preclinical Promise and Clinical Challenges for Innovative Therapies Targeting Liver Fibrogenesis
Addissouky, T. A., Ali, M. M. A., Sayed, I. E. T. E., Wang, Y., Baz, A. E., Elarabany, N., & Khalil, A. A. (2023) · Archives of Gastroenterology Research · doi:10.33696/gastroenterology.4.044 · Cited by 35
Puri, M., & Sonawane, S. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26093988 · Cited by 41
“These changes were correlated with heightened HSC activa-Int tion and collagen deposition, indicating a direct role of LSEC dysfunction in fibrosis progression [45].”
Nets in fibrosis: Bridging innate immunity and tissue remodeling
Ma, X., Ji-pin, L., Li, M., Qi, G., Wei, L., & Zhang, D. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112516 · Cited by 33
Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis
Addissouky, T. A., Ali, M. M. A., Sayed, I. E. T. E., & Wang, Y. (2024) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-024-00283-y · Cited by 49
“These compounds blunt liver, lung, kidney, and cardiac fibrosis by blocking receptor-mediated Smad signaling [5, 59–65].”
BackgroundRecent advances in polymeric nanoparticles for the treatment of hepatic diseases
Gao, F., Feng, X., & Li, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1528752 · Cited by 42
Ferroptosis in Liver Disease: Natural Active Compounds and Therapeutic Implications
Wu, Z., Zhu, Y., Liu, W., Balasubramanian, B., Xu, X. L., Yao, J., & Lei, X. J. (2024) · Antioxidants · doi:10.3390/antiox13030352 · Cited by 29
“Inhibition of HSCs activation, or induction of HSCs death, may be two effective ways to reverse LF [172].”
BackgroundLiu, Q., Li, J., Li, X., Zhang, L., Yao, S., Wang, Y., Tuo, B., & Jin, H. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5429 · Cited by 24
“Although research on the mechanisms of liver fibrosis has made great progress and certain progress has been made in the study of antifibrotic therapy, there are no effective drugs for the treatment of liver fibrosis, and advanced liver fibrosis can be treated only by liver transplantation (5,8).”
BackgroundZhang, J., Zhang, J.-X., Feng, Q.-Y., Shi, L., Guo, X., Sun, H., & Song, J. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119119 · Cited by 30
Mekawy, D. M., Sabry, D., Sabry, R. M., & Abozeid, N. F. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09343-6 · Cited by 18
“Then, the TβRI phosphorylates and activates its substrates, the suppressor of mothers against decapentaplegic (SMAD) [14] and non-SMAD pathways [ 15].”
BackgroundBeyond Encapsulation: Exploring Macrophage-Fibroblast Cross Talk in Implant-Induced Fibrosis
Sudarsanam, P. K., Alsema, E. C., Beijer, N. R. M., van Kooten, T. G., & de Boer, J. (2024) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2023.0300 · Cited by 20
“79,80 In a study, the influence of cardiac inflammation on ECM was observed in patients with heart failure patients.”
Sokal-Dembowska, A., Jarmakiewicz-Czaja, S., & Filip, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011187 · Cited by 19
“Various cells, including Kupffer cells (KCs), hepatocytes, and numerous signaling pathways, can regulate HSC activation and are potential therapeutic targets that can influence the reversal of fibrosis [25].”
BackgroundYe, L., Huang, J., Liang, X., Guo, W., Sun, X., Shao, C., He, Y., & Zhang, J. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155916 · Cited by 17
A guide to pathophysiology, signaling pathways, and preclinical models of liver fibrosis
Sultana, M., Islam, M. A., Khairnar, R., & Kumar, S. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112448 · Cited by 16
Chen, W., Wang, P., Xie, Y. H., Xie, D., Wang, H., Bu, N., Lin, J., Wu, M., Xia, H., Cheng, C., et al. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111507 · Cited by 15
The preparation, modification and hepatoprotective activity of chitooligosaccharides: A review
Liu, P., Chen, W., Wu, D., Zhang, Z., Li, W., & Yang, Y. G. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134489 · Cited by 16
Kim, J.-W., Tung, H., Ke, M., Xu, P., Cai, X., Xi, Y., Xu, M., Ren, S., Huang, Y., Bhowmik, A., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001133 · Cited by 13
Li, R., Tai, Y., Zhang, X., Liu, Z., Si, H., Kong, D., Zhao, L., Li, J., & Midgley, A. C. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202500101 · Cited by 15
Nanogene editing drug delivery systems in the treatment of liver fibrosis
Wang, Q., Jia, S., Wang, Z., Chen, H., Jiang, X., Li, Y., & Ji, P. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1418786 · Cited by 13
“…and abnormal deposition of extracellular matrix (ECM), which is a self-repair mechanism of the liver in response to chronic injury caused by various aetiological factors, and hepatic fibrosis ultimately progresses to advanced liver diseases such as cirrhosis and hepatocellular carcinoma (3, 4).”
BackgroundGolgi protein 73 in liver fibrosis
Szternel, Ł., Sobucki, B., Wieprzycka, L., Krintus, M., & Panteghini, M. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119999 · Cited by 12
Endoplasmic reticulum stress in liver fibrosis: Mechanisms and therapeutic potential
Wang, T., Xia, G., Li, X., Gong, M., & Lv, X. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167695 · Cited by 16
Hussein, J., Medhat, D., El‐Bana, M. A., El‐Naggar, M. E., Omara, E. A. A., & El‐Daly, S. M. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105796 · Cited by 11
Luo, Y., Zhao, X., Wang, R., Zhan, X., Zhang, T., He, T., Jing, J., Li, J., Li, F., Zhang, P., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.12.024 · Cited by 10
Didamoony, M. A., Soubh, A. A., & Ahmed, L. A. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01784-7 · Cited by 9
“However, it could be years before meaningful improvement is seen, depending on the severity of the disease [63].”
Recent advances in the role of polysaccharides in liver diseases: a review
Wang, J., Wang, H., Yang, X., Wang, K., & Zhang, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1535717 · Cited by 12
Notch signaling in cancer: metabolic reprogramming and therapeutic implications
Wang, S., Lv, H.-L., Nie, R., Liu, Y., Hou, Y., Chen, C., Tao, X.-Y., Luo, H.-M., & Li, P.-F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1656370 · Cited by 14
Baj, J., Kołodziej, M., Kobak, J., Januszewski, J., Syty, K., Portincasa, P., & Forma, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910233 · Cited by 10
“Injury to the liver by, for example, viruses or bacteria, followed by the activation of the immune system, the secretion of cytokines, including the transforming growth factor-β (TGF β ), or the release of reactive oxygen species (ROS) are signals for the activation of hepatic stellate cells [112].”
BackgroundZhang, X., Zeng, Y., Ying, H., Hong, Y., Xu, J., Lin, R., Chen, Y., Wu, X., Cai, W., Xia, Z., et al. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.117511 · Cited by 9
Wang, H., Chen, C., Xue, M., Zhang, Y., Chen, K., Sun, B., Wang, P., Tong, X., Yu, X., Li, J., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108996 · Cited by 8
Coffee for the liver: a mechanistic approach
Vargas-Pozada, E. E., Ramos‐Tovar, E., Márquez-Quiroga, L. V., Ortega-Carballo, K. J., & Muriel, P. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117338 · Cited by 10
Immunometabolic integration in therapeutic strategies for managing MASLD
González-Serrano, S., Onoiu, A.-I., Camps, J., & Joven, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1693753 · Cited by 8
Zhou, Q., Zhang, X., Chen, S., Chang, F., Wan, K., Wu, C., Wang, X., Zhang, W., & Jiang, H. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119120 · Cited by 8
Yuan, Y., Liu, X., Zhou, T., Zhou, Z., Gong, M., & Li, Y. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13599 · Cited by 8
“Liver fibrosis (LF) is a common pathological consequence of chronic liver injury caused by various factors. it is character‑ ized by an imbalance between the synthesis and degradation of collagen, leading to excessive accumulation of fibrous tissue in the liver (1,2).”
Biological Aging and Uterine Fibrosis in Cattle: Reproductive Trade-Offs from Enhanced Productivity
Matsuno, Y., & Imakawa, K. (2025) · Cells · doi:10.3390/cells14130955 · Cited by 10
“Targeting HSC activation, inducing HSC apoptosis, or modulating fibrosis-related signaling pathways are promising strategies for promoting liver fibrosis regression [177].”
The combination of tetracyclines effectively ameliorates liver fibrosis via inhibition of EphB1/2
Han, Y., Song, H., Li, Y., Li, R., Chen, L., Gao, B., Chen, Y., & Wang, S. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111261 · Cited by 7
Zhang, Q., Wang, L., Li, H., Wu, F., Tang, Z., Li, H., Wang, C., & Zhao, X. (2024) · Food Reviews International · doi:10.1080/87559129.2024.2396841 · Cited by 8
“[91,92] Using HSC-T6 hepatic stellate cells as an in vitro assay system, it was discovered that gartanin dramatically suppressed HSC-T6 vitality and decreased collagen content, indicating that gartanin could be helpful for the treatment of liver fibrosis.”
Zhang, C., Bai, Y., Yin, Q., Li, J., Huang, K., & Qiu, M. R. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114569 · Cited by 7
Shi, S., Zhang, M., Zhu, C., Zhu, S., Yu, J., Sui, Q., Xu, J., Ren, J., Zhang, J., Chen, P., et al. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111586 · Cited by 8
Zhang, C., Zhao, Y., Yan, H., Guo, J., & Yu, G. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02694-4 · Cited by 8
Wang, C., 罗敏, Chen, Q., Zheng, L., Jiang, T., & Dai, M. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121450 · Cited by 6
Dai, G., Lin, J., Jiang, Y., Liu, X., Chen, P., Zhang, Y., Song, Z., Zhuang, X., Cong, J., Li, Y., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1517226 · Cited by 5
“Without effective intervention, this continuous deposition of ECM proteins can lead to the formation of fi brous scars, distortion of liver structure, and the subsequent development of liver cirrhosis, hepatocellular carcinoma (HCC), and liver failure (9 – 11).”
Li, L., Jin, Y., Li, T., Lv, B., Yuan, D., Li, X., & Yuan, J. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70144 · Cited by 4
“Various flavonoid compounds suppress the activation of hepatic stellate cells (HSCs) by inhibiting the transforming growth factor-beta (TGF-β ) pathway and reducing the expression of alpha-smooth muscle actin ( α -SMA) [93–96].”
Zhang, Y., Xu, A., Jin, Y., Gao, J., & He, J. (2025) · Medicine · doi:10.1097/md.0000000000043064 · Cited by 4
Zhao, Y., Pei, L., Ding, K., Wang, J., & Liu, T. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126069 · Cited by 8
Chen, S., Gao, J., Chen, J., Huang, Y., Wang, L., Lin, J., Zhao, M., Shen, Y., Zhao, G., & Cheng, Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.147642 · Cited by 4
Vitisin A inhibits liver fibrosis by promoting Nrf2/HO-1 pathway and inhibiting Cuproptosis
Ding, S., Hu, D., Pan, Y. F., Wang, J., & Wang, L. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-27836-7 · Cited by 4
The Role of Thermal Immunomodulation in Postoperative Wound Repair with a Focus on Hepatic Surgery
Pietrzyk, B., Mikolajczyk, J., Joniec, A., Fajferek, T., & Kaczara, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031473 · Cited by 5
“However, maintaining perioperative normothermia and preventing hypothermia is well documented as beneficial for reducing complications such as the following: hemostatic disturbances, impaired immune response, surgical site infections, bleeding, and delayed healing [109].”
Li, J., Vranjkovic, A., Read, D., Delaney, S. P., Stanford, W. L., Cooper, C., & Crawley, A. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1375485 · Cited by 4
“As liver damage progresses to advanced liver fi brosis (AF) and cirrhosis, there is an increased risk for progression to end-stage liver disease, portal hypertension, esophageal varices, hepatic encephalopathy, susceptibility to infections, and hepatocellular carcinoma (HCC) (4 – 6).”
BackgroundTenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy
Wang, Y., Yang, L., Xu, Q., Liu, T., He, H., Liu, L., & Yin, L. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics17010032 · Cited by 5
“The persistent inflammatory response in the liver not only rebuilds and reforms the ECM but also ex-acerbates metabolic reprogramming [6].”
Yang, J., Wang, Y., Zhuo, L., Lu, G.-J., Zhang, M., Huang, J., Li, Y., Liu, W., Qi, J., Zhu, A., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18081228 · Cited by 3
“Several key pathways contribute to HSC activation, including TGF-β signaling pathway, PDGF signaling pathway, Hippo signaling pathway, and ROS [11].”
Kupffer cells: Orchestrators of liver physiology
Qin, C., Chen, Y., & Tang, L. (2026) · Liver Research · doi:10.1016/j.livres.2026.01.004 · Cited by 4
“80 Additionally, KCs express vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs), enhancing the proliferation of LSECs and promoting liver regeneration.”
Self-citationZeng, C., Lu, Q., Zhao, Q., & Li, J. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08312-w · Cited by 3
“Damaged hepatocytes produce substances that stimulate HSCs and inflammatory cells, releasing damage-associated molecular patterns (DAMPs) to activate Kupffer cells and HSCs, inducing inflammatory and fibrotic responses [12, 13].”
Targeting macrophages in liver fibrosis
González del Barrio, L., Ipsen, D. H., Pfister, D. R., Hancz, D., & Scott, C. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835489 · Cited by 3
Lin, C.-H., Cheng, C., Chiou, Y., Wang, I., & Kuo, C. (2024) · Intervirology · doi:10.1159/000542355 · Cited by 2
Biomedical applications of organoids derived from the digestive system
Xu, Z., Lei, Z., Cheng, Q., Gao, Y., & Xiang, Y. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1599384 · Cited by 2
“Hepatic fibrosis represents a critical phase in the progression of chronic liver disease, characterized by the abnormal accumulation and excessive deposition of extracellular matrix within the liver due to repeated exposure to various stimuli (Pei et al., 2023).”
Long noncoding RNA H19 in liver development and disease
Montoya-Durango, D. E., & Gobejishvili, L. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112413 · Cited by 2
The different effects of four adenosine receptors in liver fibrosis
Yang, L., Gao, Z., Wang, X., Wu, X., Li, S., Dong, K., & Zhu, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1424624 · Cited by 7
“Liver fi brosis is characterized by excessive deposition of the extracellular matrix (ECM) in the liver (Parola and Pinzani, 2019; Pei et al., 2023).”
BackgroundPhycocyanin a nutraceutical with antioxidant activity
Fernández-Rojas, B., Hernández‐Juárez, J., & Pedraza‐Chaverrí, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21873-6.00004-x · Cited by 4
Rong, G., Liu, J. H., Yang, Y., Wang, S., & Cao, W. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177522 · Cited by 2
Pei, H., Chen, Y.-Q., Wu, F., Zhang, Y., Zhang, X., Li, J.-Y., Pan, L., Chen, Y., & Huang, Y. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002956 · Cited by 2
“For advanced fibrosis, the only available treatment is liver transplantation, but this method has its limitations [5].”
Lebedeva, E. I., Babenka, A. S., & Shchastniy, A. T. (2024) · Genes and Cells · doi:10.17816/gc622891 · Cited by 2
Metformin Attenuates Hepatic Fibrosis in Mice by Altering the Gut Microbiota
Huang, X., Peng, C., Ye, Z., Wei, K., & Zhang, Z. (2024) · Hepatitis Monthly · doi:10.5812/hepatmon-149965 · Cited by 1
miR-372-3p represses hepatic stellate cell activation via the RhoC/ROCK pathway
Ou, S., Tang, X., Li, Z., Ouyang, R., Lei, Y., Chen, G., & Du, L. (2025) · Cytotechnology · doi:10.1007/s10616-025-00715-9 · Cited by 1
“However, the continued activation of HSCs will lead to further progression of liver fibrosis (Pei et al. 2023).”
Asouri, S. A., Motallebi, M., Karimi, M., Taheri, M. A., Aghadavod, E., Qanbari, M., Mirzaei, H., Amiri, S., & Shahaboddin, M. E. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10625-z · Cited by 5
Autophagy in age-related liver disease
Palacios, R., Francés, D. E., & Motiño, O. (2025) · Geromedicine · doi:10.70401/geromedicine.2025.0005 · Cited by 4
Kunnaja, P., Chansakaow, S., Taychaworaditsakul, W., Intatham, S., Jaijoy, K., Wittayapraparat, A., Yusuk, P., Suksathan, R., & Sireeratawong, S. (2025) · Biology · doi:10.3390/biology15010017 · Cited by 2
“Under normal conditions, antioxidants protect hepatocytes from oxidative stress–induced apoptosis, whereas in pathological states such as fibrosis or cancer, they can modulate signaling pathways (e.g., p53, NF-κ B) to promote apoptosis and limit disease progression [55].”
Xiao, Y., Li, J., Xiang, L., & Xiu, W. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1767998 · Cited by 1
Alsugoor, M. H., Alsuhaymi, N., Moustafa, P. E., Madani, M. E., Afifi, N. A., Derzawy, A., Ibrahim, N. E., Fayed, H. M., & Awdan, S. A. E. (2026) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2026.106964 · Cited by 2
Guo, X., Liu, Y.-H., Huang, B.-N., Tai, Y., Liu, X.-K., Du, R., & Jin, X.-J. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158399 · Cited by 1
Chen, X., Su, J., Huang, W., Li, Y., & Zhang, J. (2026) · Metabolites · doi:10.3390/metabo16060413 · Cited by 1
“The progression of MASLD frequently culminates in hepatic fibrosis, which is closely associated with hepatocellular stress, chronic inflammation, and the fibrotic process [21,22].”
Unifying and unique roles of non-coding RNA biomarkers in liver and heart fibrosis
Boichenko, V., Frolova, S., Voellenkle, C., Zaccagnini, G., Ferrero, P., Bassareo, P. P., Luciani, G. B., Gorelik, J., & Martelli, F. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119607 · Cited by 2
“Liver fibrosis is a dynamic wound-healing response to chronic liver injury, arising from diverse aetiologies such as viral infection, excessive alcohol consumption, metabolic disorders, or toxic exposure, that drives ECM accumulation that disrupts liver structure and function [16].”
Extracellular matrix stiffness in chronic liver disease: From mechanisms to treatments
Xi, Z.-H., Sun, W.-J., Li, M., Dong, Q.-Q., Dong, X., Qiao, Z.-L., Tao, H., Yang, J., & Lu, C. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118194 · Cited by 1
Virus infections and cancers: from mechanisms to therapeutics
Li, Y., Yu, W., Yun, J., Wang, J., Liu, Y., Su, H., Guo, H., Yang, J., Yan, Y., Yan, X., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00485-6 · Cited by 2
“Similar mechanisms are widely observed in KSHV [169, 227], HCV [211, 212], and MCPyV [201, 202].”
Zhang, Z., Sun, M., Yang, Y., Xie, J., Li, Y., Lin, Y., Liu, Y., Liao, Y., & Lin, L. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158631 · Cited by 2
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis
Tavaglione, F., & Loomba, R. S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103023 · Cited by 1
Kazmi, A., & Sultana, T. (2024) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2024.100016 · Cited by 2
Luo, X., Chen, K., Zhang, J., Yao, Z., Guo, C., Qu, Y. H., Lu, L., & Mao, Y. (2025) · The FASEB Journal · doi:10.1096/fj.202401985rr · Cited by 1
Chen, X., He, M., Zhang, X., Liao, S., Zeng, Z., Zhu, L., Tu, B., Long, Q., & Lin, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-5315197/v1 · Cited by 1
Onoiu, A.-I., Murray, L., Gerardin, Y., Singh, G., Egger, R., González-Serrano, S., Cambra-Cortés, V., Jiménez-Franco, A., Guilarte, C., Parada, D., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8725050/v1 · Cited by 1
Meng, D., & Ren, S. (2024) · The Natural Products Journal · doi:10.2174/0122103155273345231210170121
Lebedeva, E. I., Shchastniy, A. T., Babenka, A. S., Мартинков, В. Н., Zinovkin, D. A., & Nadyrov, E. A. (2024) · Morphology · doi:10.17816/morph.632588
Nwafor, J. A., Eze, G. I., & Innih, S. O. (2024) · Journal of Experimental and Clinical Anatomy · doi:10.4314/jeca.v21i2.17
Belyaev, G. P., Vyshtakalyuk, A. B., Парфенов, А. А., Galyametdinova, I. V., Semenov, V. E., & Васильевич, З. В. (2025) · Učënye zapiski Kazanskogo universiteta. Seriâ Estestvennye nauki/Učënye zapiski Kazanskogo universiteta. Seriâ Estestvennye nauki/Učenye zapiski Kazanskogo gosudarstvennogo universiteta. Seriâ Estestvennye nauki · doi:10.26907/2542-064x.2025.2.276-296 · Cited by 1
Thijeel, K. S., Thuwaini, M. M., & Jasim, A. K. (2025) · Romanian Journal of Medical Practice · doi:10.37897/rjmp.2025.2.13
“This condition can lead to the excessive buildup of extracellular matrix, which can subsequently lead to cirrhosis and liver cancer, posing a serious risk to human health [13].”
Circular RNAs in Liver Diseases
Nokkeaw, A., & Ariyachet, C. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-981-96-9428-0_21 · Cited by 1
Thijeel, K. S., Thuwaini, M. M., Jasim, A. K., & Abbas, H. J. (2025) · Journal of Applied Hematology · doi:10.4103/joah.joah_82_25
Dantas, B. P., Magri, M. C., Manchiero, C., Nunes, A. K. D. S., Prata, T. V. G., & Tengan, F. M. (2025) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20250241
Lv, H., Li, C., Li, Q. H., Luo, Q., Chen, Y., Liu, A. A., Du, X., Cao, Q., Zhang, P., & Meng, L. (2025) · Natural Product Research · doi:10.1080/14786419.2025.2567641
Feng, X., Lu, X., Huang, L., Yang, S.-L., Jiang, Q., & Wei, W. (2026) · Microchemical journal (Print) · doi:10.1016/j.microc.2025.116488
Multi-omics analysis decipher effect of ECM degradation and depositionon hepatocellular carcinomaPreprint
Zeng, X., Guo, L. Q., Fenglan, W., Wang, P., & Guo, H. (2025) · Research Square · doi:10.21203/rs.3.rs-7998082/v1
Premnath, V., & Veerappapillai, S. (2026) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-025-05547-z
Metadata
- Authors
- Pei, Q., Yi, Q., & Tang, L.
- Affiliations
- Chongqing University (CN)
- Southwest Medical University (CN)
- Corresponding author
- Yi, Qian
- Tang, Liling
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-06-02
- Volume
- 24
- Issue
- 11
- Pages
- 9671
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10253436
- OpenAlex
- W4379230272
- Cited by
- 121
- References
- 167
- Citations by year
- 2026: 37 · 2025: 43 · 2024: 36 · 2023: 5
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (32271363, 2021-JYJ-71, 2022NSFSC1368)
- Luzhou Science and Technology Program (32271363, 2021-JYJ-71, 2022NSFSC1368)
- Sichuan Science and Technology Program (32271363, 2021-JYJ-71, 2022NSFSC1368)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- liver fibrosis, fibrosis resolution, hepatic stellate cells, hepatic stellate cell activation, extracellular matrix accumulation, liver cirrhosis, hepatocellular carcinoma, antifibrotic therapy, signaling pathways, therapeutic target, apoptosis
- MeSH terms
- Fibrosis, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Hepatic Stellate Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.